Cassava Sciences SAVA, a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative ...

Cassava Sciences (SAVA)’ trial for simufilam 50 mg or 100 mg for mild-to-moderate Alzheimer’s disease, named “REFOCUS-ALZ,” has been “terminated” in a “sponsor decision,” according ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Expected To Support Operations Into 2026 Conference Webcast Scheduled for Today at 8:30AM ET AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical ...

WHAT'S NEXT? If you suffered a loss in Cassava Sciences, Inc. during the relevant time frame, you have until February 10, 2025 to request that the Court appoint you as lead plaintiff. Your ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal ...

Cassava Sciences, a Texas biopharma company, had developed simufilam to treat (and possibly cure) Alzheimer’s disease, the most common form of dementia that afflicts tens of millions of people ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...